New combo before lung surgery shows promise but trial cut short
NCT ID NCT03237377
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study tested giving immunotherapy drugs (durvalumab with or without tremelimumab) along with radiation before surgery for stage III non-small cell lung cancer. Only 9 people took part, and the trial was stopped early. The goal was to see if this combination was safe and feasible without delaying surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Durvalumab (immunotherapy) and tremelimumab (immunotherapy) plus thoracic radiation
What this could lead to
If successful, this approach could improve outcomes for patients with stage III lung cancer by shrinking tumors before surgery and potentially reducing recurrence.
What could go wrong
This was a very small, early pilot study (only 9 participants) that was terminated early, so results are limited. Combining immunotherapy with radiation also carries risks of serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Johns Hopkins Bayview Medical Center
Baltimore, Maryland, 21224, United States
-
Princess Margaret Cancer Centre
Toronto, Ontario, Canada